Markets:

Overview

News

Currencies

International

Treasuries

Can-Fite Biopharma Ltd Sponsored ADR (Israel) (NY:CANF)

0.2810 -0.0080 (-2.77%)

Streaming Delayed Price Updated: 12:05 PM EST, Dec 17, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Can-Fite Biopharma Ltd Sponsored ADR (Israel)

< Previous 1 2 3 4 5 6 7 Next >

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

April 25, 2024

Via Benzinga

Long-term Complete Response to Can-Fite's Namodenoson in Patient with Advanced Liver Cancer: Article Published in a Leading Scientific Journal

April 25, 2024

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH

April 15, 2024

From Can-Fite BioPharma Ltd.

Via Business Wire

Can Fite Biofarma: Q4 Earnings Insights ↗

March 28, 2024

Via Benzinga

Recap: Can Fite Biofarma Q3 Earnings ↗

November 30, 2023

Via Benzinga

Can-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients

April 03, 2024

From Can-Fite BioPharma Ltd.

Via Business Wire

CANF Stock Earnings: Can Fite Biofarma Beats EPS, Beats Revenue for Q4 2023 ↗

March 28, 2024

CANF stock results show that Can Fite Biofarma beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.

Via InvestorPlace

Can-Fite Reports 2023 Financial Results and Clinical Update

March 28, 2024

From Can-Fite BioPharma Ltd.

Via Business Wire

Namodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe Conference

March 11, 2024

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite Broadens its Strong Intellectual Property (IP) for NASH: Received Patent Allowance in Canada

February 28, 2024

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indication

January 30, 2024

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite: Top Scientific Journal Published Positive Data from the COMFORT-1 Phase III Psoriasis Study

January 29, 2024

From Can-Fite BioPharma Ltd.

Via Business Wire

The Anti-Obesity Effect of Can-Fite’s Namodenoson: Molecular Mechanism of Action in Pre-clinical and Human Studies

December 20, 2023

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite Received FDA Positive Response to Psoriasis Pediatric Plan

December 18, 2023

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite’s Namodenoson for the Treatment of Pancreatic Cancer Patients: Progress in Clinical Development

December 04, 2023

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite Reports Third Quarter 2023 Financial Results and Clinical Update

November 30, 2023

From Can-Fite BioPharma Ltd.

Via Business Wire

Why Is Liver Cancer Focused Can-Fite BioPharma Stock Trading Higher Today? ↗

November 21, 2023

Can-Fite BioPharma Ltd (NYSE: CANF) announced that a patient who participated in the Phase 2 Liver Cancer Study and was treated with namodenoson had a complete response and overall survival of

Via Benzinga

Can-Fite: Complete Response and 6.9 Years Overall Survival in a Patient with Advanced Liver Cancer Treated with Namodenoson

November 21, 2023

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite Issues Business Update: All Clinical Programs and Business Development Activities Remain Solidly on Track

November 01, 2023

From Can-Fite BioPharma Ltd.

Via Business Wire

Can Fite: Namodenoson Inhibits Pancreatic Carcinoma Published in Leading Scientific Journal; Robust anti-Cancer Effect & Molecular Mechanism of Action

October 30, 2023

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite to Harness Artificial Intelligence to Develop Novel Anti-Cancer Drugs

October 26, 2023

From Can-Fite BioPharma Ltd.

Via Business Wire

Matson To Rally Around 36%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

October 24, 2023

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page

Via Benzinga

Can-Fite to Share its Rare Genetic Disease Lowe Syndrome Novel Treatment with Orphan Drug Japanese Companies

October 09, 2023

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite Novel Approach for the Treatment of Pancreatic Carcinoma with Namodenoson Receives Appreciation of the American Association of Cancer Research (AACR)

September 27, 2023

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite to Share with Investors Latest Oncology and Rare Genetic Disease Developments at the H.C. Wainwright 25th Annual Conference

September 07, 2023

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite Reports Second Quarter 2023 Financial Results & Progress in Two Pivotal Phase III Clinical Studies

August 31, 2023

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite Enters Rare Genetic Disease Field Based on impactful findings of a Fondazione Telethon and Naples University Researcher showing Piclidenoson is efficacious in Treating Lowe Syndrome

August 24, 2023

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite Submitted to FDA a Pediatric Plan to Allow Registration of Piclidenoson for the Treatment of Adolescents with Psoriasis

August 18, 2023

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite: Granted Breakthrough Abstract Award for Namodenoson in Treatment of Advanced Liver Cancer by ASCO Conquer Cancer Foundation

July 17, 2023

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite to Present at the Emerging Growth Conference on July 13, 2023

July 07, 2023

From Can-Fite BioPharma Ltd.

Via Business Wire

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.